Aeglea BioTherapeutics (AGLE) Prices 11.65M Share Common Stock Offering at $4.75/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St climbs after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Aeglea BioTherapeutics (AGLE) Announces $100M Proposed Public Offering of Common Stock, Warrants
April 27, 2020 4:25 PM EDTAeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases, today announced a proposed underwritten public offering in which it intends to offer and sell $100 million of shares of its common stock and, in lieu of common stock, to offer and sell to... More
